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ABSTRACT
Aims: To present 12 new variants of uracil mustard having drug-like properties and cytotoxic
functional group, by utilizing uracil mustard (uramustine) as a lead compound. Utilize rigorous
substructure and similarity of a molecular scaffold to determine drug like variants. Physicochemical
properties determined indicate the variants have favorable drug-likeness.
Study Design: Conduct molecular database search utilizing features of substructure and similarity
based upon uracil mustard.
Place and Duration of Study: Department of Chemistry, Medicinal Chemistry Study Section,
University of Nebraska at Omaha, Omaha Nebraska between January 2015 to March 2015.
Methodology: Uracil mustard consists of the pyrimidine derivative uracil, having the bifunctional
nitrogen mustard cytotoxic moiety covalently bonded onto the ring. A systematic search, utilizing
substructure component and similarity, within an in-silico database search successfully determined
12 variants. Rigorous criteria for drug-likeness was implemented to screen potential candidates
_____________________________________________________________________________________________________
*Corresponding author: Email: rbartzatt@unomaha.edu;
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that included the application of the Rule of 5. In addition, maintaining the cytotoxic moiety of
nitrogen mustard was crucial.
Results: A total of 12 variants of uracil mustard was identified after an extensive molecular
database search using rigorous criteria. All 12 variants, and including uracil mustard, showed zero
violations of the Rule of 5, thereby indicating favorable drug-likeness. Values of polar surface area
2
for all compounds at less than 80 Angstroms are suitable for central nervous system penetration.
Polar surface area, number of atoms, and Log P for all compounds increased as the molecular
weight increases. Structure substituents include nitrogen mustard groups, hydroxyl, alkyl and
carbonyl moieties. Cluster analysis discerned greatest similarity among members of this group.
Conclusion: Applying rigorous search criteria within a molecular data base, for comparison and
reject, successfully identified 12 variants of uracil mustard that show favorable drug-likeness in
addition to cytotoxic capability. The design of new antitumor agents is important for increasing
efficacy of the clinical treatment of cancer.

Keywords: Uracil mustard; uramustine; cancer; leukemia; lymphoma.

ABBREVIATIONS
Term: PSA, polar surface area; A, angstroms; MW, molecular weight; n Atoms, number of atoms;
nOHNH, number hydroxyl and amine groups; nON, number of oxygen and nitrogen atoms.

1. INTRODUCTION

Uracil mustard has been shown to bring about a
dramatic relief in patients having Hodgkin’s
disease and multiple myeloma, in addition to be
well tolerated [10]. After extensive clinical trials
this agent has been found effective in treatment
of granulocytic leukemias [10] and childhood
acute leukemia [11]. Uracil mustard is declared
an effective drug for controlling thrombocytosis
with minimal effects on leukocytes and
erythrocytes [12]. In the case of elderly patients
fighting non-Hodgkin’s lymphoma, the fifth most
common malignancy for male and female in the
United States, the use of uracil mustard would be
effective [13,6,7]. This lymphoma originates in
the lymphatic system, causing greater than
18,000 deaths in the United States annually.
Uracil mustard and 5-fluorouracil in combination,
have been shown to be an extremely effective
chemotherapy [14].

Uramustine or uracil mustard is an alkylating
chemotherapy agent that is particularly effective
for the treatment of lymphomas, Non-Hodgkin’s
lymphoma, chronic lymphocytic leukemia,
chronic myelogenous leukemia and chronic
leukemias [1,2]. It is used in lymphatic
malignancies such as non-Hodgkin's lymphoma.
Nitrogen mustard agents alkylate the DNA and
thereby induce damage to the DNA, which in turn
is a cytotoxic effect primarily to cancer cells [1].
This due to the take up of uracil due to the need
to form nucleic acids during rapid cycles of cell
division. The DNA damage (cross-linking) leads
to apoptosis of the affected cells. This agent is
cell cycle-phase nonspecific. Chemically it is a
derivative of nitrogen mustard and uracil. Notable
among its advantages are: 1) Small dose
requirement; 2) Uniform tolerability; 3) Simple
regimen requirements [1].

In-silico studies have been successful for
characterizing the molecular activity of uracil
mustard with cellular targets such as DNA [15].
Optimization of molecular scaffolding with
concurrent elucidation of physicochemical
properties
has
been
successful
for
characterization of drug efficacy treating dermal
neoplasm [16]. This study presents 12 variants of
uracil
mustard
resulting
from
in-silico
substructure and similarity mining with use of
rigor enjoined by uracil mustard scaffolding
parametric limitation.

Previous studies have shown the efficacy of
uracil
mustard
for
the
treatment
of
thrombocythemia, chronic lymphatic leukemia,
and lymphoma [3]. Investigators record objective
improvement in patients having solid tumor,
lymphoma, and leukemia [4,5]. Clinical studies
have also demonstrated the effectiveness of
uracil mustard for treatment of Hodgkin disease,
non-Hodgkin lymphoma, and chronic lymphatic
leukemia [6- 9].
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GraphPad InStat 3.0 GraphPad Software, Inc.,
San Diego California USA, www.graphpad.com).

2. MATERIALS AND METHODS
2.1 Molecular Modeling and Assembly of
Molecular Variants

3. RESULTS AND DISCUSSION
Uracil mustard (uramustine) is known to be
effective in the treatment of a multitude of
neoplastic diseases. Data mining for substructure
replacement has undergone progress in recent
years and presents an efficacious tool for drug
design, particularly with the presence of effective
parent constructs that are applied in seeding the
mining process [15,16]. Utilizing uracil mustard
as the parent compound for drug design (see
compound 1, Fig. 1) the outcome nitrogen
mustard agents 2 through 13 were determined
after an algorithmic search process generating
numerous candidates, of which, included those
having unfavorable bioavailability attributes (ie.
high formula weight and polar surface area) to be
identified and eliminated. This rate of ruination
makes it necessary of having information
descriptive of successful candidates, concerning
the
desired
(drug-like)
physicochemical
properties. Therefore, substituent replacement is
clearly an important approach in rational drug
design [17].

Molecular modeling (2-D) was accomplished
utilizing ACD/Chem Sketch modeling v. 10.00
(Advanced Chemistry Development, 110 Yonge
Street, Toronto Ontario, M5C 1T4 Canada). In
silico structure search for a substituent
replacement was accomplished using chemical
substructure and similarity search with Molsoft
L.L.C. (Molsoft L.L.C. 11199 Sorrento Valley
Road, S209 San Diego, CA 92121) and
Molinspiration (Molinspiration Chemiformatics,
Nova ulica 61, SK-900 26 Slovensky Grob,
Slovak Republic). Various properties such as
polar surface area, violations of Rule of 5,
molecular volume, number of oxygens, nitrogens,
amines (-NHn) and hydroxyls (-OH), were
determined using Molinspiration Properties
Calculations
module
(Molinspiration
Chemiformatics, Nova ulica 61, SK-900 26
Slovensky Grob, Slovak Republic). Biological
activity of all compounds was determined by
Molinspiration drug-likeness and bioactivity
scoring (Molinspiration Chemiformatics, Nova
ulica 61, SK-900 26 Slovensky Grob, Slovak
Republic).

In general, the aromatic heterocyclic organic
pyrimidine ring remains in addition to the
bifunctional cytotoxic nitrogen mustard group that
renders the alkylating antineoplastic action. The
parent compound with 12 variants are presented
in Fig. 1. The variants of uracil mustard are
essentially derivatives having an additional
substitution in place of the hydrogen (-H) located
onto N-3. Substituents located onto N-3 then will
introduce variations of pharmaceutical properties
such as Log P, polar surface area, molecular
weight, etc. It is vital to maintain a favorable
drug-likeness of properties while inducing
variation that would benefit the clinical efficacy of
the compound. The drug-likeness of the
compounds was monitored and rigorously made
to adhere to the Rule of 5, which is a robust
approach to identify potential drugs having good
membrane permeability and orally active (easily
absorbed) [18]. An orally active drug will have no
more than one violation of the following
criteria [18]: 1) No more than 5 hydrogen bond
donors (-OH and -NHn); 2) Not more than 10
hydrogen bond acceptors (all nitrogen or oxygen
atoms); 3) A molecular mass less than 500
Daltons; 4) An octanol-water partition coefficient
Log P not greater than 5.

2.2 Pattern Recognition
To identify underlying associations and patterns
within the descriptors multivariate numerical data
matrix, then various pattern recognition
techniques were implemented. Included in this
analytical approach is a hierarchical cluster
analysis accomplished by KyPlot v. 2.0 Beta 15
(copyright Koichi Yoshioka 1997-2001). Other
pattern recognition elucidation by K-means
nonhierarchical cluster analysis and discriminant
analysis were performed by PAST v. 1.80
(copyright Oyvind Hammer, D.A.T. Harper 19992008).

2.3 Numerical Analysis of Multivariate
Physicochemical Properties
Descriptive statistical analysis, Pearson r, and
coefficient of determination for all numerical data
where indicated was performed by Windows 7
Microsoft Office Professional Plus 2013 EXCEL
(EXCEL 2013). Screening for numerical outliers
was done by Grubb’s Test (extreme studentized
deviate) by GraphPad Software (2236 Avenida
de la Playa, La Jolla, CA 92037 USA). Multiple
regression analysis was performed by GraphPad
InStat v. 3.0 for Windows 95 (HJ Motulsky,

The molecular structure of uracil mustard, with
12 variants are presented in Fig. 1. Notably, each
52
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structure possesses the nitrogen mustard group
responsible for the nucleic acid alkylating
cytotoxic activity (located at the C-5 position). All
Cl

variations of uracil mustard (#2 to #13) have
substituents on the N-3 position. Beginning with
compound #2, the N-3 substituent is an acyl
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Fig. 1. Molecular structure of uracil mustard and its variants. The molecular scaffolding
includes the pyrimidine derivative uracil, alkylating nitrogen mustard moiety (covalently
bonded to C-5), hydroxyl, alkyl, and carbonyl moieties (collectively attached to the pyrimidine
uracil on N-3)
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group: (CH3C(=O)-),
), followed by compound #3
having a propanoyl group (CH3CH2C(=O)-),
followed by compounds #4 to #8 having alkyl
substitutions:(CH3(CH2)nC(=O)-)) where n = 2 to
6, respectively. Compounds #2 to #8 constitute a
homologous series that differ by a constant unit
or generally a (-CH2-) group.. These agents which
have been shown to have similar and often times
increasing beneficial
ficial medicinal activity [19].
Likewise, for compounds #11 to #13 shown in
Fig. 1, the N-3
3 position has substituents
(-C(OH)(CH2)nCH3) where n = 3 to 5,
respectively. Hence, two homologous series of
compounds have been identified within this
group of compounds.

each cluster) and utilizing
tilizing Euclidian distance (the
most common distance measure, are the
geometric distance in multidimensional space) is
presented in a divisive vertical dendrogram (see
Fig. 2).
Interestingly, the compounds #2 to #8 are
clustered together to be more simil
similar to each
other and joined at node C. It follows, that
compounds #9 to #13 are likewise determined to
be more similar to each other and joined at node
D. These two clusters are in turn joined at super
node B. The super node A joins node B to the
parent compound
mpound (#1). This analysis has
distinguished the parent compound uracil
mustard (#1) from the 12 variations of ring
substituents.

Physicochemical properties useful for evaluating
pharmaceutical potential are presented for all 13
compounds, see Table 1. Noteworthy points
include the very strong positive correlation
(Pearson r > 0.9000) for Log P to the number of
atoms, molecular weight, rotatable bonds, and
molecular volume. In addition, there is a strong
positive correlation (Pearson r > 0.6000) for polar
surface area to the number
mber of atoms, molecular
weight and molecular volume. The range in Log
P values for this group of compounds is broad
(0.563 to 3.968), having value of 3.405. Previous
studies have shown the efficacy of varying the
Log P of medicaments in the case of
antineoplastic drugs [16], as well as antibacterial
drugs [20-22].
22]. In these studies the medicinal
activity of the agent was increased
ed in the case of
antibacterial drugs or enhanced for antineoplastic
agents.

Fig. 2. Hierarchical cluster analysis utilizing
single linkage with Euclidean distance.
Compound 1 is uracil mustard joined at node
A with all remaining compounds. Node B
joins compounds 2 to 13 into two sub
clusters under node C (2, 3, 4, 5, 6, 7 and 8)
and node D (9, 10, 11, 12, and 13)

Notably, all compounds have zero violations of
the Rule of 5, indicating favorable membrane
permeation and absorption (i.e. drug-likeness).
drug
Values of polar surface area are kept low, having
2
a small range of 68.9 Angstroms to 78.3
2
Angstroms . These values again indicate
favorable
avorable drug absorption [23]. Previous
investigation as to drug-likeness
likeness of known
pharmaceuticals suggest that all compounds #1
to #13 would be greater than 50% absorbed from
the intestinal tract [23]. These properties support
the potential of the 12 variants of uracil mustard.

Other trends in properties can be discerned by
non-hierarchical cluster analysis.
nalysis. K-means
K
cluster analysis is used to classify observations
through a K number of clusters, and aims to find
a grouping of objects which maximizes or
minimizes some evaluating criterion [24]. Results
of K-means
means cluster analysis places these
compoundss into four distinct clusters, as follows:
Cluster 1) compounds #4, #5, #9, #10; cluster 2)
compounds #6, #7, #11, #12; cluster 3)
compounds #8, #13; cluster 4) uracil mustard
(#1), compounds #2, and #3. Therefore, a
connectivity is identified among the pa
parent
compound uracil mustard and variants #2 and
#3. To follow, the analogy is determined by
discriminant analysis being a process used
todetermine
which
variables
discriminate
between two or more naturally occurring groups.

Further understanding of the underlying
relationships between these compounds is
accomplished using pattern recognition method
of hierarchical cluster analysis (a multilevel
hierarchy, where clusters at one level are joined
as clusters
usters at the next level) [24]. Results of
hierarchical cluster analysis utilizing a single
linkage (minimum distance between elements of
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Table 1. Physicochemical properties of compounds
Drug

1
uramustine
2
3
4
5
6
7
8
9
10
11
12
13

Log P Polar
surface
2
area (A )
0.563 68.9

Number Molecular Number
of
weight
O&N
atoms
15
252.1
5

Number
of –OH
& -NH2
2

Rule
Rotatable Molecular
of 5
bonds
volume
3
violations
(A )
0
5
199.0

0.885
1.387
1.947
2.452
2.957
3.462
3.968
1.298
1.858
2.363
2.868
3.373

18
19
20
21
22
23
24
20
21
22
23
24

1
1
1
1
1
1
1
2
2
2
2
2

0
0
0
0
0
0
0
0
0
0
0
0

75.2
75.2
75.2
75.2
75.2
75.2
75.2
78.3
78.3
78.3
78.3
78.3

294.1
308.2
322.2
336.2
350.3
364.3
378.3
324.2
338.2
352.3
366.3
380.3

6
6
6
6
6
6
6
6
6
6
6
6

5
6
7
8
9
10
11
7
8
9
10
11

234.9
251.8
268.6
285.4
302.2
319.0
335.8
273.9
290.7
307.5
324.3
341.1

A2 =Angstroms2; A3 =Angstroms3

Results of discriminant analysis indicate the
commonality among uracil mustard (#1) to
compounds #9, #10, #11, #12, and #13
(compounds having alcoholic homologous
series). Distinct from these compounds are those
compounds #2, #3, #4, #5, #6, #7, and #8
(compounds having alkanoyl homologous
series).

series of drug agents and found in other studies
[20-22].
The general goal of multiple regression is to
learn more about the relationship between
several independent or predictor variables and a
dependent or criterion variable. One use of
multiple regression is a prediction or estimation
of
an
unknown,
dependent
Y
value
corresponding to a set of independent X values.
A second application of multiple regression is to
understand the functional relationships between
the dependent and independent variables, to try
to see what might be causing the variation in the
dependent variable [24]. Multiple regression
analysis of the descriptors presented in Table 1
resulted in a mathematical description that
accounts for 100% of the variance within the
model (R2 = 1.000). The properties applied
include molecular weight (MW), polar surface
area (PSA), number of atoms (nAtoms), number
of hydroxyl and amine groups (nOHNH), number
of oxygen & nitrogen atoms (nON) and molecular
volume (MV). The model is expressed as follows:

Grubbs' test, also known as the maximum
normed residual test or extreme studentized
deviate test, is a statistical test used to detect
outliers in a univariate data set assumed to come
from a normally distributed population [25].
Analysis of all 13 compounds for outliers utilizing
Grubb’s test, showed no outliers among the
values of Log P, the number of atoms, molecular
weight, number of oxygen/nitrogen atoms, and
molecular volume. These findings, shows
consistency with the parent drug uracil mustard.
Other discernable and highly linear trends of
these compounds are the steadily increasing
polar surface area (Pearson r = 0.6887) and
number of atoms (Pearson r = 0.9996) as
dependent variables, when compared to
molecular weight (independent variable), see
Fig. 3.

MW = 36.521 + 0.74068(PSA) +5.900(nAtoms)
- 2.155(nOHNH) -1.036(nON) + 0.5455(MV)
The equation describing the model can be used
to predict important molecular properties that will
allow the additional design of analogous
compounds.

A 2-way plot of Log P (dependent variable) to
molecular
weight
(independent
variable)
indicated an increasing strong exponential trend
2
(R = 0.9307), see Fig. 4. The increase of Log P
within a homologous series of compounds has
been determined in previous studies to generally
enhance and improve medicinal activity [19]. The
rise in Log P values corresponding increase of
molecular weight is consistent with homologous

The diversity of potential drug targets is so
enormous, that it is possible to find a common
denominator for all of them [26]. The strategy
which leads to success is focus on particular
drug classes and the development of the specific
activity score for each of these classes. This is
55
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accomplished for compounds presented in this
study and listed in Table 2. The distribution of
activity scores for the four most important drug
classes is presented in Table 2. For ion channel
modulator activity and drug-likeness, the best
score falls between -1.30 to 0.50 [26]. For kinase
inhibitor activity and drug-likeness, the best score
falls between -1.30 to 0.50 [26]. For protease
inhibitor activity and drug-likeness, the best score

falls between -1.10 to 0.50 [26]. For other
enzyme inhibitor activity and drug-likeness, the
best score falls between -1.10 to 0.50 [26].
Therefore, all compounds (#1 to #13) presented
in this study show the best biological activity
score for active compounds and drug-likeness.
This is further evidence that these variants of
uracil mustard will be effective and useful in
clinical application.

Fig. 3. Comparison of polar surface area and number of atoms (dependent variables) to
compound molecular weight (independent variable). Number of atoms are highly linear with
2
very strong positive relationship (Pearson r = 0.9996, coefficient of determination, R = 0.9993)
with increase of molecular weight. Polar surface area is highly linear to increase of molecular
weight with a strong positive relationship (Pearson r = 0.6887, coefficient of determination
2
R = 0.4743)
4.5
4
3.5

R² = 0.9307

Log P

3
2.5
2
1.5
1
0.5
0
250

270

290

310

330

350

370

390

Molecular Weight
Fig. 4. Trend for Log P compared to molecular weight increase is a steady increase along
2
(coefficient of determination, R = 0.9307, correlation coefficient r = 0.9647)
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Table 2. Biological activity of compounds by score
Drug
1 uramustine
2
3
4
5
6
7
8
9
10
11
12
13

Ion channel
modulator
-0.76
-1.02
-0.92
-0.88
-0.83
-0.79
-0.76
-0.73
-0.39
-0.37
-0.35
-0.33
-0.32

Kinase
inhibitor
-0.50
-0.05
-0.08
0.04
0.08
0.10
0.11
0.11
0.33
0.34
0.35
0.35
0.34

Protease
inhibitor
-1.03
-0.52
-0.48
-0.40
-0.32
-0.27
-0.23
-0.20
-0.15
-0.09
-0.03
0.0
0.02

Enzyme
inhibitor
-0.26
-0.14
-0.11
0.0
0.02
0.02
0.01
0.01
0.16
0.17
0.18
0.17
0.17

The design of anticancer drugs is an important
aspect for the clinical treatment of cancer.
Improvement in the treatment and improvement
of clinical outcome is enhanced by the
introduction of the versatile and novel drugs
initiated by rational drug design. Presented here
are 12 variations of uracil mustard that have
shown useful drug-likeness and possess the
cytotoxic nitrogen mustard alkylating functional
group. Further studies of novel drug designs
would be useful for advancing the treatment of
cancer.

design following rigorous criteria for substructure
and similarity. Design of novel or improved
anticancer agents ultimately will benefit the
patient as well as the clinical choices for
treatment of neoplastic disease. Variation of
physicochemical properties can benefit the
efficacy of anticancer drugs and should be
further investigated for the benefit of patients.

4. CONCLUSION

ETHICAL APPROVAL

Twelve structures which are variants of uracil
mustard were identified utilizing rigorous
physicochemical criteria of substructure and
similarity to this nitrogen mustard anticancer
agent. Additions to the scaffold of uracil mustard
included hydroxyl groups, alkyl carbon chains,
and carbonyl groups. The wide range of Log P
values from 0.885 to 3.968 contributes to a
diverse potential in the use of these cytotoxic
variants of uracil mustard, as shown in previous
studies. Hierarchical cluster analysis and
discriminant
analysis
distinguished
uracil
mustard from these variants, however K-means
cluster analysis identified two variants having an
acyl (CH3C(=O)-) group (#2) and propanoyl
(CH3CH2C(=O)-) group (#3) bonded to the #3
nitrogen of uracil base to be most similar to uracil
mustard. As compound molecular weight
increases the polar surface area, number of
atoms and Log P increase, respectively. Multiple
regression determined the equation accounting
for 100% of variance modeling. Producing
cytotoxic variants of uracil mustard showing zero
violations of the Rule of 5 (good oral availability),
this study demonstrates the efficacy of drug
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